Update on the diagnosis and treatment of hepatocellular carcinoma

Nicole D. Ferrante, Anjana Pillai, Amit G. Singal

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Hepatocellular carcinoma (HCC) is the fourth-leading cause of cancer-related mortality worldwide and the fastest-rising cause of cancer-related death in the United States. Given the strong association between tumor stage and prognosis, HCC surveillance is recommended in high-risk patients, including patients with cirrhosis from any etiology. The diagnosis can be made based on characteristic imaging findings, with histologic confirmation primarily reserved for patients with atypical imaging findings. Over the last 2 decades, the treatment landscape for HCC has experienced significant advances. Curative therapies, including liver transplantation and surgical resection, are available to patients with early-stage HCC; however, recent data have expanded the potentially eligible patient population. Locoregional therapies, including transarterial chemoembolization and transarterial radioembolization, continue to be standard therapies for patients with intermediate-stage disease. The greatest advances have been observed for patients with advanced HCC, where there are now multiple first- and second-line options that can prolong survival by up to 2 years when used sequentially. The increasing complexity of HCC treatment options underlies the necessity for multidisciplinary care, which has been associated with increased survival. This article reviews data on best practices for early detection and diagnosis of HCC and the current status of treatment options.

Original languageEnglish (US)
Pages (from-to)506-516
Number of pages11
JournalGastroenterology and Hepatology
Issue number10
StatePublished - Oct 2020


  • Diagnosis
  • Hepatocellular carcinoma
  • Immunotherapy
  • Screening
  • Treatment

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Update on the diagnosis and treatment of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this